openPR Logo
Press release

Ebola Virus Vaccine Market & Pipeline Insight

06-29-2017 09:36 AM CET | Health & Medicine

Press release from: Kuick Resarch

Ebola virus infection, which was previously called Ebola hemorrhagic fever was discovered in 1976. The infection caused due to ebola virus originates from four different strains of ebola virus. These viruses generally are known to affect non-human primates, and are transmitted from wild animals to the humans and among the latter, it is known to spread through human-to-human transmission. The natural hosts of ebola virus are Fruit bats, which belong to the Pteropodidae family.

Ebola virus is mostly found among primates in the African region, (mainly in the remote villages of Central and West Africa, near tropical rainforests) and in the Philippines. Other than Africa, this infection has been observed in regions like Republic of Congo, Gabon, Sudan, Ivory Coast and Uganda.

Download Report:

https://www.kuickresearch.com/report-Ebola-Virus-Vaccine-Market-&-Pipeline-Insight.php

In terms of treatment, till date, there is not standard treatment method for Ebola hemorrhagic fever. Only supportive therapy is available. Also, there is no licensed vaccine for ebola virus infection which is of clinical use. The researchers have been trying to better understand this virus and target its ecological reservoirs in order to get a deeper understanding of the cause and nature of the outbreaks of this disease. There are currently many experiments in the laboratories which are focusing on developing an appropriate vaccine for the prevention of this disease, but no success has been met till now.

The pharma companies have a significant opportunity in the field of ebola virus infections in terms of developing drugs, vaccines and introducing measures to control and prevent the spread of the disease. After the success of the clinical candidates, and the market approval of these drugs or vaccines, it is most likely that there could a significant demand for these products from the physicians and patients. Additionally, due to the nature of the disease, these products would be priced at a premium, which would eventually yield high revenues for the companies which would earn a significant return on investment.

“Ebola Virus Vaccine Market & Pipeline Insight” Report Highlight:

* Ebola Virus Infection Market Overview
* Ebola Vaccine Clinical Trial Insight by Phase, Company & Country
* Ebola Vaccine in Clinical Trials: 26 Vaccine
* Majority Ebola Vaccine in Preclinical Phase: 15 Vaccines
* Ebola Vaccines by Mechanism of Action, Drug Class, Route of administration, * Patent Analysis & Licensing Status

For Report Sample Contact: neeraj@kuickresearch.com or

visit: https://www.kuickresearch.com

Recent Publications:

* Global Cancer Immunotherapy Market & Clinical Trials Outlook 2022
* Global CAR T Cell Therapy Market & Clinical Trials Insight 2022
* Global Dendritic Cell Cancer Vaccine Market & Clinical Trials Outlook 2023
* Global Microcapsules Drug Delivery Market Opportunity Outlook 2022
* Global Controlled Drug Delivery Market & Clinical Trial Outlook 2022
* Global Cancer Antibody Drug Conjugates Market & Pipeline Insight 2022
* Global B Cell Lymphoma Market & Clinical Pipeline Insight 2022

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ebola Virus Vaccine Market & Pipeline Insight here

News-ID: 601367 • Views: 498

More Releases from Kuick Resarch

Global Orphan Drug Rare Disease Market Clinical Trials Forecast 2028
Global Orphan Drugs Clinical Trials Insight Report Highlights: • Clinical Insight On More Than 400 Marketed Orphan Drugs • Clinical Insight On More Than 1300 Orphan Drugs in Clinical Trials • Orphan Designated Drug Clinical Status by Indication & Country • Global Market Opportunity More Than USD 350 Billion • Market Exclusivity & Patent Protection Criteria for Orphan Drugs • Global & Regional Orphan Drug Market Sales Opportunity • Orphan Drug Reimbursement Policy • Orphan Clinical Pipeline Overview
Global CD233 Antibody Market Clinical Trials Intelligence 2028
Global CD233 Inhibitors Trials Intelligence Report Highlights: • Global CD233 Inhibitors Market Dynamics • Clinical Approaches to Target CD233 Inhibitors • Role of CD233 Inhibitors in Cancer, Autoimmune Disorders • Number of CD233 Inhibitors Drug In Trials • CD233 Inhibitors Approved Patent Insight • CD233 Inhibitors Trials By Phase, Company, Country, Indication • Company Agreement/Partnership/Deals For Ongoing Trials • Global CD233 Inhibitor Market Future Outlook For Report Sample Contact neeraj@kuickresearch.com The successful application of the anti-CTLA-4 and anti-PD-1/PD-L1
Global Gene Therapy Market Clinical Trials Research Insight 2028
Global Gene Therapy Market & Clinical Trials Intelligence Report Highlights • Global Market Gene Therapy Landscape USD 24 Billion Opportunity • Comprehensive Commercial & Clinical insight on 16 Approved Gene Therapies • Gene Therapy Products Dosage & Price Analysis • Comprehensive Clinical Insight On 1700 Gene Therapies In Clinical Trials • Information On 45 Orphan Designated Gene Therapies By Indication, Country, Company • Global Gene Therapy Clinical Trials Insight By Phase, Country, Formulations, Company, Indication, Target •
TROP2 Targeted Therapy Trodelvy Market Clinical Trials Insight 2026
Global TROP2 Antibody Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights: • Research Methodology • Global & Regional Market Analysis • Global TROP2 Antibody Market Opportunity Assessment: > USD 4 Billion • Market and Drug Sales Insight 2020 Till 2026 • Approved Drug In Market: 1 Drugs • Approved TROP2 Antibody Patent, Price and Sales insight 2020 Till 2026 • Future Market Assessment By Indication Till 2026 • Ongoing Clinical Trials Assessment by Status, Phase & Region • Key Market Dynamics • Competitor Landscape Download Report:

All 5 Releases


More Releases for Ebola

Global Ebola Vaccine Market Huge Growth Opportunity between 2020-2025
LP INFORMATION recently released a research report on the Ebola Vaccine market analysis, which studies the Ebola Vaccine's industry coverage, current market competitive status, and market outlook and forecast by 2025. Global "Ebola Vaccine Market 2020-2025" Research Report categorizes the global Ebola Vaccine market by key players, product type, applications and regions,etc. The report also covers the latest industry data, key players analysis, market share, growth
Ebola Vaccine Market Opportunity Analysis, 2018-2026
Ebola virus disease (EVD) causes viral hemorrhagic fever. It is a life threatening disease, which is spread to humans from animals. Direct contact with body fluids of infected person is one of largest causes of spread of this infection. Symptoms of Ebola disease include high fever, vomiting, sore throat, diarrhea, headache and muscular pain, and in few cases, internal or external bleeding. Although, there is no cure for Ebola virus
Ebola Treatment Market: Global Industry Analysis and Forecast 2016 - 2024
Ebola viral infection was first observed in The Democratic Republic of Congo (named after a river called Zaire) in 1976. Ebola is a viral disease which frequently causes lethal haemorrhagic fever in humans. The harmful consequences of Ebola viral infection are that the viruses can be used as potential biological weapon. The symptoms of Ebola viral infection include sudden onset of fever, sore throat, headaches, extreme tiredness, vomiting, skin rash,
2017-2022 Global Ebola Virus Vaccine Industry Forecast Report
ReportsWeb.com has announced the addition of the “Global Ebola Virus Vaccine Market Research Report 2017-2022” The report focuses on global major leading players with information such as company profiles, product picture and specification. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD) , market share and growth rate of Ebola Virus Vaccine in these regions, from 2012 to 2022 (forecast) , covering North America, Europe,
Ebola Treatment Market to Undertake Strapping Growth During 2016-2024
Ebola viral infection was first observed in The Democratic Republic of Congo (named after a river called Zaire) in 1976. Ebola is a viral disease which frequently causes lethal haemorrhagic fever in humans. The harmful consequences of Ebola viral infection are that the viruses can be used as potential biological weapon. The symptoms of Ebola viral infection include sudden onset of fever, sore throat, headaches, extreme tiredness, vomiting, skin rash,
combit Employees Support Ebola Victims and Syrian Refugees
Constance/Germany, 12/02/2014 – Among the numerous reports on crisis regions, those that remain particularly etched in our memory are the images of the critically ill people in West Africa who are infected with Ebola and of the suffering of the Syrian refugees. For that reason, the employees of the software company combit in Constance have decided to help. The fight against the Ebola virus is costly, and the Syrian health